Nothing Special   »   [go: up one dir, main page]

de Melo, 2021 - Google Patents

The impact of Lama2-deficiency on cell cycle regulation and survival

de Melo, 2021

View PDF
Document ID
5756837202842567555
Author
de Melo C
Publication year
Publication venue
PQDT-Global

External Links

Snippet

Laminin α2 chain-deficient congenital muscular dystrophy (LAMA2-CMD) is caused by recessive mutations in the LAMA2 gene. This neuromuscular disease is diagnosed at birth or within the first few months of life and is characterized by hypotonia and severe muscle …
Continue reading at repositorio.ulisboa.pt (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Similar Documents

Publication Publication Date Title
Al-Qusairi et al. T-tubule biogenesis and triad formation in skeletal muscle and implication in human diseases
Clemen et al. Desminopathies: pathology and mechanisms
Zhu et al. Loss of ARHGEF6 causes hair cell stereocilia deficits and hearing loss in mice
Bunnell et al. β-Actin specifically controls cell growth, migration, and the G-actin pool
US20230036788A1 (en) Compositions and methods of using tyrosine kinase inhibitors
US20090169540A1 (en) Use Of An Antagonist Of Epac For Treating Human Cardiac Hypertrophy
Nicol et al. Becoming female: ovarian differentiation from an evolutionary perspective
Melo The impact of Lama2-deficiency on cell cycle regulation and survival
Gieseler et al. Molecular, genetic and physiological characterisation of dystrobrevin-like (dyb-1) mutants of Caenorhabditis elegans
US8404442B2 (en) Methods for identification of bone anabolic agents
JP7325466B2 (en) Vectors and methods for regenerative medicine
US20100016221A1 (en) Method of degrading protein by chaperone-mediated autophagy
JP2021531292A (en) Composition for the treatment of sarcopenia or disuse atrophy
Ribeiro How Lama2-deficiency impacts myoblast differentiation in a mouse model for LAMA2-congenital muscular dystrophy
JP2022535796A (en) Animal model of idiopathic pulmonary fibrosis, its construction method and use
Zscheppang et al. ErbB4 is an upstream regulator of TTF-1 fetal mouse lung type II cell development in vitro
WO2019180664A1 (en) Method for preventing or modulating fibrosis and fibrotic response associated with the integrated stress response
US20210244827A1 (en) Anc80 encoding sphingolipid-metabolizing proteins
WO2024029535A1 (en) Agent for detecting structurally abnormal protein and agent for reducing structurally abnormal protein
Peters-Golden et al. Kruppel-like factor 4 as a therapeutically tractable brake on lung fibroblast activation which promotes resolution of pulmonary fibrosis
Russo Structural and functional consequences of p63 mutations causative of AEC syndrome
Dookun Senescence as a potential therapeutic target for ischaemia-reperfusion injury following acute myocardial infarction
WO2023205741A1 (en) Chimeric efferocytic receptors improve apoptotic cell clearance and alleviate inflammation
Raman THE ROLE OF MATRICELLULAR SIGNALING IN POLYCYSTIC KIDNEY DISEASE
Mughal Regulation of mitochondrial function by Myocardin during cardiac development and disease